CSV February 23, 2023 through February 23, 2025 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
MORPHINE	IM	*Revision*	Online	26-Apr-2019	1-May-2019	*NA*	*NA*	In Row 4 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
SULFATE EXTENDED-RELEASE CAPSULES	PURITIES/*Organic Impurities*	*Bulletin (Official November 01, 2018)*						Column 1 of *Table 5*: Change Morphine related compound B[b] to: Morphine related compound B (anhydrous)[b]
HYPROMELLOSE PHTHALATE	IMPURITIES/*Chloride and Sulfate <221>, Chloride*	*Harmonization (Official May 01, 2019)*	Online	26-Apr-2019	1-May-2019	*NA*	*NA*	In *Analysis*: Change [?]Add 1 mL of silver nitrate TS to the *Standard solution* and then add a 50-mL portion of the *Sample solution*. Mix and allow to stand for 5 min protected from direct sunlight. Compare the turbidity of the solutions.?(NF 1-May-2019) to: Add 1 mL of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								silver nitrate TS to the *Standard solution*. Add 1 mL of silver nitrate TS to a 50-mL portion of the *Sample solution*. After mixing, allow each solution to stand for 5 min protected from direct sunlight. Compare the turbidity of the solutions.
ISOPHANE INSULIN HUMAN SUSPENSION	ASSAY/ *Procedure*	*Interim Revision Announcement (Official January 01, 2019)*	Online	29-Mar-2019	1-Apr-2019	*NA*	*NA*	In *Standard solution*: Change USP Insulin Beef RS to: USP Insulin Human RS
SCOPOLAMINE HYDROBROMIDE	IDENTIFICATION/*B.*	*First Supplement to USP41–NF36*	8420	29-Mar-2019	1-Apr-2019	*NA*	*NA*	In *Sample solution*: Change 50 mg/mL of alcohol to: 50 mg/mL in

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								water
PREDNISOLONE SODIUM PHOSPHATE	*Related compounds*	*USP41–NF36*	3416	29-Mar-2019	1-Apr-2019	*NA*	*NA*	In *Table 1*: Add Prednisolone sodium phosphate 1.00 — —
MERCAPTOPURINE	IMPURITIES/*Organic Impurities*	*USP41–NF36*	2587	29-Mar-2019	1-Apr-2019	*NA*	*NA*	Change *Sample solution*: 0.12 mg/mL of Mercaptopurine in *Solution A*. [NOTE—Inject the *Sample solution* within 1 h of preparation.] to: *Sample stock solution*: 0.5 mg/mL of mercaptopurine in a mixture of methanol and *Solution A* (1:9) prepared as follows. Transfer a suitable quantity of Mercaptopurine

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to an appropriate volumetric flask, add methanol equivalent to 10% of the final volume, and shake to dissolve. Dilute with *Solution A* to volume. *Sample solution*: 0.12 mg/mL of mercaptopurine in *Solution A* from the *Sample stock solution*. [NOTE—Inject the *Sample solution* within 1 h of preparation.]
BUMETANIDE TABLETS	ASSAY/ *Procedure*	*Second Supplement to USP41–NF36*	Online	29-Mar-2019	1-Apr-2019	*NA*	*NA*	In *Sample solution*: Change Nominally 0.05 mg/mL of bumetanide prepared as

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								follows. to: Nominally 125 µg/mL of bumetanide prepared as follows.
RUTIN	CHEMICAL INFORMATION	*USP41–NF36*	4841	29-Mar-2019	1-Apr-2019	*NA*	*NA*	Change 3-Rhamnoglucoside of 5,7,3',4'-tetrahydroxyflavonol; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4*H* -chromen-4-one -3-yl 6-*O*-?-L-rhamnopyranosyl-?-D-glucoside [250249-75-3]. to: 3-Rhamnoglucoside of 5,7,3',4'-tetrahydroxyflavonol trihydrate; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4*H*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-chromen-4-one -3-yl 6-*O*-?-L-rhamno pyranosyl-?-D-glucoside trihydrate [250249-75-3].
METAXALONE	IDENTIFICATIO N/*B.*	*USP41–NF36*	2611	29-Mar-2019	1-Apr-2019	*NA*	*NA*	Change The retention time of the major peak of the *Sample solution* corresponds to that of the *Sample solution*, as obtained in the *Assay*. to: The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the *Assay*.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
MESNA TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*Second Supplement to USP41–NF36*	8906	22-Feb-2019	1-Mar-2019	*NA*	*NA*	In USP Mesna Related Compound A RS: Change 2-(Acetylthio)ethane-1-sulfonic acid. $C_4H_8O_4S_2$ 184.22 to: 2-(Acetylthio)ethane-1-sulfonic acid, potassium salt, crystal adduct with potassium chloride. $C_4H_7KO_4S_2$? KCl 296.86 AND In USP Mesna Related Compound B RS: Change 2,2?-Disulfanediylbis(ethane-1-sulfonic acid). $C_4H_{10}O_6S_4$ 282.36 to: 2,2?-Disulfane

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								diylbis(ethane-1-sulfonic acid), dipotassium salt, crystal adduct with sodium chloride. $C_4H_8K_2O_6S_4$? NaCl 416.98
DEXMEDETOMIDINE HYDROCHLORIDE	CHEMICAL INFORMATION	*USP41–NF36*	Online	22-Feb-2019	1-Mar-2019	*NA*	*NA*	This erratum applies to the *USP-NF* ONLINE platform only. See https://www.usp nf.com/sites/def ault/files/usp_pd f/EN/february_2 019_errata_ima ge1.pdf for correction
READENTS	*Solutio ns/Volumetric Solutions/0.01 N Sodium Hydroxide VS*	*USP41–NF36*	5770	22-Feb-2019	1-Mar-2019	*NA*	*NA*	See https://www.usp nf.com/sites/def ault/files/usp_pd f/EN/february_2 019_errata_ima ge1.pdf for correction
FLUDROCORTIIM		*Second*	8843	22-Feb-2019	1-Mar-2019	*NA*	*NA*	In footnote a:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
SONE ACETATE TABLETS	PUR ITIES/*Organic Impurities*/*Table 1*	*Supplement to USP41–NF36*						Change 9-Fluoro-11?,17 ,21-trihydroxypr egn-4-ene-3,20-dione 21-acetate. to: 9-Fluoro-11?,17 ,21-trihydroxypr egn-4-ene-3,20-dione.
ANALYTICAL DATA—INTERPRETATION AND TREATMENT	MEASUREMEN PT PRINCIPLES AND VARIATION	*USP42–NF37*	7129	22-Feb-2019	1-Mar-2019	*NA*	*NA*	See https://www.usp nf.com/sites/def ault/files/usp_pd f/EN/february_2 019_errata_ima ge1.pdf for correction
OXANDROLONE	*Related compounds*	*USP41–NF36*	3072	22-Feb-2019	1-Mar-2019	*NA*	*NA*	In footnote 4 of the second table: Change Methyl-(1,17?-di hydroxy-17?-me thyl-1,3-seco-2-nor-5?-androsta ne-3-oate. to: Methyl 1,17?-d ihydroxy-17?-m ethyl-1,3-seco-2

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-nor-5?-androstan-3-oate.
CARBINOXAMINE MALEATE	IMPURITIES/*Organic Impurities*	*Second Supplement to USP41–NF36*	8786	22-Feb-2019	1-Mar-2019	*NA*	*NA*	In *Standard stock solution*: Change (equivalent to 0.05 mg/mL of USP Carbinoxamine Maleate RS free base) and 0.05 mg/mL each of USP Carbinoxamine Related Compound A RS, USP Carbinoxamine Related Compound B RS, and USP Carbinoxamine Related Compound C RS free base to: (equivalent to 0.05 mg/mL of carbinoxamine) and 0.05 mg/mL each of USP

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Carbinoxamine Related Compound A RS, USP Carbinoxamine Related Compound B RS, and USP Carbinoxamine Related Compound C RS (as the free base) AND In the *Standard solution*: Change (equivalent to 0.001 mg/mL of USP Carbinoxamine Maleate RS free base) and 0.001 mg/mL each of USP Carbinoxamine Related Compound A RS, USP Carbinoxamine Related

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Compound B RS, and USP Carbinoxamine Related Compound C RS free base to: (equivalent to 0.001 mg/mL of carbinoxamine) and 0.001 mg/mL each of USP Carbinoxamine Related Compound A RS, USP Carbinoxamine Related Compound B RS, and USP Carbinoxamine Related Compound C RS (as the free base) AND In the *Analysis*: Change C_S = concentration of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								USP Carbinoxamine Maleate RS free base to: C_S = concentration of USP Carbinoxamine Maleate RS (as the free base)
PRAZOSIN HYDROCHLORIDE COMPOUNDED ORAL SUSPENSION	ASSAY/ *Procedure*	*Second Supplement to USP41–NF36*	8945	22-Feb-2019	1-Mar-2019	*NA*	*NA*	In the *Mobile phase*: Change tetramethylammonium hydrochloride to: tetramethylammonium hydroxide
DIVALPROEX SODIUM EXTENDED-RELEASE TABLETS	ASSAY/ *Procedure*	*USP41–NF36*	1358	22-Feb-2019	1-Mar-2019	*NA*	*NA*	In *Buffer*: Change 0.5 g/L of citric acid and 0.4 g/L of dibasic sodium phosphate in water to: 0.5 g/L of anhydrous citric

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								acid and 0.4 g/L of anhydrous dibasic sodium phosphate in water
AMITRIPTYLINE HYDROCHLORIDE TABLETS	IMPURITIES/*Organic Impurities*	*Second Supplement to USP41–NF36*	8759	22-Feb-2019	1-Mar-2019	*NA*	*NA*	In *Analysis*: Change r_U = peak response of amitriptyline related compound A, amitriptyline related compound B, or nortriptyline hydrochloride from the *Sample solution* r_S = peak response of amitriptyline related compound A, amitriptyline related compound B, or nortriptyline hydrochloride from the *Standard*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution to: r_U = peak response of amitriptyline related compound A, amitriptyline related compound B, or nortriptyline from the *Sample solution* r_S = peak response of amitriptyline related compound A, amitriptyline related compound B, or nortriptyline from the *Standard solution*
MESNA	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*Second Supplement to USP41–NF36*	8904	22-Feb-2019	1-Mar-2019	*NA*	*NA*	In USP Mesna Related Compound A RS: Change 2-(Acetylthio)ethane-1-sulfonic

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								acid. $C_4H_8O_4S_2$ 184.22 to: 2-(Acetylthio)ethane-1-sulfonic acid, potassium salt, crystal adduct with potassium chloride. $C_4H_7KO_4S_2$? KCl 296.86 AND In USP Mesna Related Compound B RS: Change 2,2?-Disulfanediylbis(ethane-1-sulfonic acid). $C_4H_{10}O_6S_4$ 282.36 to: 2,2?-Disulfanediylbis(ethane-1-sulfonic acid), dipotassium salt, crystal adduct with sodium

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								chloride. $C_4H_8K_2O_6S_4$? NaCl 416.98
ARGATROBAN	CHEMICAL INFORMATION	*USP41–NF36*	346	22-Feb-2019	1-Mar-2019	*NA*	*NA*	See https://www.usp nf.com/sites/def ault/files/usp_pd f/EN/february_2 019_errata_ima ge1.pdf for correction
CALCIUM SILICATE	IM PURITIES/*Limit of Lead*	*USP41–NF36*	5240	22-Feb-2019	1-Mar-2019	*NA*	*NA*	In *Lead standard solution*: Change 1000 mg of lead/mL[4] to: 1000 mg of lead/L[4]
CARBINOXAMINE MALEATE TABLETS	IM PUR ITIES/*Organic Impurities*	*Second Supplement to USP41–NF36*	8788	22-Feb-2019	1-Mar-2019	*NA*	*NA*	In the *Standard stock solution*: Change USP Carbinoxamine Maleate RS free base) to: carbinoxamine) AND In the *Standard*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution: Change USP Carbinoxamine Maleate RS free base) to: carbinoxamine) AND In the *Analysis*: Change C_S = concentration of USP Carbinoxamine Maleate RS free base to: C_S = concentration of USP Carbinoxamine Maleate RS (as the free base)
REAGENTS	*Reagent Specifications/ 7,8-Dihydrofolic Acid*	*Second Supplement to USP41–NF36*	9052	22-Feb-2019	1-Mar-2019	*NA*	*NA*	Change *(L-Glutamic Acid, N-[4-[[(2-Amino-3,4,7,8-tetrahydro-4-pteridinyl)methyl]amino]benzoyl]-),*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: *(L-Glutamic Acid, N-[4-[[(2-Amino-3,4,7,8-tetrahydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-),*
METHYLDOPA	SPECIFIC TESTS/*Optical Rotation <781S>*	*USP41–NF36*	2666	22-Feb-2019	1-Mar-2019	*NA*	*NA*	In the *Sample solution*: Change aluminum chloride to: aluminum chloride hexahydrate
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE TABLETS	ASSAY/*Procedure/Chromatographic system*	*Second Supplement to USP41–NF36*	8781	22-Feb-2019	1-Mar-2019	*NA*	*NA*	In *Column*: Change [Note—Conditioning of the *Column* with *Solution A* and *Solution B* (80:20) to: [Note—Conditioning of the *Column* with *Solution A* and *Solution B*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								(90:10)
L104	CHROMATOGRAPHIC COLUMNS/*Packings*	*First Supplement to USP41–NF36*	8503	26-Jan-2019	1-Feb-2019	*USP42–NF37*	*Second Supplement to USP41–NF36*	Add L104—Triazol groups chemically bonded to porous silica particles, 1.5–10 ?m in diameter.
LEFLUNOMIDE	IMPURITIES/*Organic Impurities*/*Procedure 2*	*USP41–NF36*	2353	25-Jan-2019	1-Feb-2019	*NA*	*NA*	Change *Standard solution*: 0.5 µg/mL of USP Leflunomide RS, from the *Standard solution* in *Mobile phase* to: *Standard stock solution*: Proceed as directed in the *Standard solution* in the *Assay*. *Standard solution*: 0.5 µg/mL of USP Leflunomide RS

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								from the *Standard stock solution* in *Mobile phase*
SALIX SPECIES BARK DRY EXTRACT	INTRODUCTION	*USP42–NF37*	5187	25-Jan-2019	1-Feb-2019	*NA*	*NA*	Delete (This monograph is postponed indefinitely.)
SALIX SPECIES BARK	INTRODUCTION	*USP42–NF37*	5185	25-Jan-2019	1-Feb-2019	*NA*	*NA*	Delete (This monograph is postponed indefinitely.)
SALIX SPECIES BARK POWDER	ADDITIONAL REQUIREMENTS	*USP42–NF37*	5189	25-Jan-2019	1-Feb-2019	*NA*	*NA*	In *Labeling*: Change The label states the Latin binomial(s) of one or several *Salix* species included in the article. to: The label states the Latin binomial(s) of one or several *Salix* species included in the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								article. Dosage forms prepared with this article should bear the following statement: Not for use in children, women who are pregnant or nursing, or by persons with known sensitivity to aspirin. AND In *USP Reference Standards* <*11*>: Delete (This monograph is postponed indefinitely.)
SALMETEROL INHALATION POWDER	ASSAY/ *Procedure/Analysis*	*First Supplement to USP41–NF36*	Online	25-Jan-2019	1-Feb-2019	*NA*	*NA*	In the definition list: Change M_{r1} = molecular weight of salmeterol free base, 415.75 to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								M_{r1} = molecular weight of salmeterol free base, 415.57
SALIX SPECIES BARK DRY EXTRACT	ADDITIONAL REQUIREMENTS	*USP42–NF37*	5187	25-Jan-2019	1-Feb-2019	*NA*	*NA*	In *Labeling*: Change It meets the labeling requirements of *Botanical Extracts* <*565*>. to: It meets the labeling requirements of *Botanical Extracts* <*565*>. Dosage forms prepared with this article should bear the following statement: Not for use in children, women who are pregnant or nursing, or by persons with known sensitivity to

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								aspirin. AND In *USP Reference Standards* <*11*> : Delete (This monograph is postponed indefinitely.)
BENZETHONIUM CHLORIDE	IMPURITIES/*Organic Impurities/Acceptance criteria*	*First Supplement to USP41–NF36*	8297	25-Jan-2019	1-Feb-2019	*NA*	*NA*	In *Total impurities*: Change 1.0% to: NMT 1.0%
SALIX SPECIES BARK	ADDITIONAL REQUIREMENTS	*USP42–NF37*	5185	25-Jan-2019	1-Feb-2019	*NA*	*NA*	In *Labeling*: Change The label states the Latin binomial(s) of one or several *Salix* species included in the article. to: The label states the Latin binomial(s) of one or several *Salix* species

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								included in the article. Dosage forms prepared with this article should bear the following statement: Not for use in children, women who are pregnant or nursing, or by persons with known sensitivity to aspirin. AND In *USP Reference Standards* <*11*>: Delete (This monograph is postponed indefinitely.)
SALMETEROL INHALATION POWDER	PERFORMANCE TESTS	*First Supplement to USP41–NF36*	Online	25-Jan-2019	1-Feb-2019	*NA*	*NA*	In the definition list in *Particle Size Distribution by Cascade Impaction/Analysis*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Change M_{r1} = molecular weight of salmeterol free base, 415.75 to: M_{r1} = molecular weight of salmeterol free base, 415.57 AND In the definition list in *Delivered-Dose Uniformity <601>/Analysis*: Change M_{r1} = molecular weight of salmeterol free base, 415.75 to: M_{r1} = molecular weight of salmeterol free base, 415.57
SALIX SPECIES BARK POWDER	INTRODUCTION	*USP42–NF37*	5189	25-Jan-2019	1-Feb-2019	*NA*	*NA*	Delete (This monograph is postponed indefinitely.)
PANTOPRAZO	IM	*First*	8392	28-Dec-2018	1-Jan-2019	*NA*	*NA*	In *Column*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
LE SODIUM	PUR ITIES/*Organic Impurities*/*Test 2*/ *Chromatographic system*	*Supplement to USP41–NF36*						Change 4.6-mm x 12.5-cm; 5-?m packing L1 to: 4-mm x 12.5-cm; 5-?m packing L1
METACRESOL	IDENTIFICATION/*B.*	*USP41–NF36*	2605	28-Dec-2018	1-Jan-2019	*NA*	*NA*	Change The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the *Assay*. to: The retention time of the metacresol peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
VITAMIN A	ADDITIONAL REQUIREMENTS	*USP41–NF36*	4327	28-Dec-2018	1-Jan-2019	*NA*	*NA*	*Assay*. Change Delete the following ?•*USP Reference Standards <11>* USP Retinyl Acetate RS USP Retinyl Palmitate RS ?(CN 1-May-2018) to: •*USP Reference Standards <11>* USP Retinyl Acetate RS USP Retinyl Palmitate RS
ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES	PERFORMANCE TESTS/ *Dissolution <11>/Test 3/Buffer stage*	*Revision Bulletin (Official March 01, 2018)*	Online	28-Dec-2018	1-Jan-2019	*NA*	*NA*	In the *Standard solution*: Change 0.25 M sodium hydroxide, to: 0.25 N sodium hydroxide, AND In the *Sample solution*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Change 0.25sodium hydroxide, to: 0.25 N sodium hydroxide,
TELMISARTAN AND HYDROCHLOROTHIAZIDE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>/Test 1/ Chromatographic system*	*Revision Bulletin (Official February 01, 2018)*	Online	28-Dec-2018	1-Jan-2019	*NA*	*NA*	In *Flow rate*: Change The flow rate goes back to 0.6 mL to: The flow rate goes back to 0.6 mL/min
OLEYL OLEATE	CHEMICAL INFORMATION	*USP41–NF36*	5471	28-Dec-2018	1-Jan-2019	*NA*	*NA*	Change 532.92 to: 532.94
HOMATROPINE HYDROBROMIDE	*Limit of tropine*	*USP41–NF36*	2038	28-Dec-2018	1-Jan-2019	*NA*	*NA*	In *Tropine reference solution*: Change 0.4 mg per mL. to: 0.4 mg per mL in *Diluent*.
TRIAZOLAM TABLETS	*Uniformity of dosage units <905>*	*USP41–NF36*	4202	28-Dec-2018	1-Jan-2019	*NA*	*NA*	In *Mobile phase* and *Chromatographic system*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Change Proceed as directed in the *Assay* under *Triazolam*. to: Proceed as directed in the *Assay*. AND In *Procedure*: Change Proceed as directed for *Procedure* in the *Assay* under *Triazolam*. to: Proceed as directed in the *Assay*.
OXYBUTYNIN CHLORIDE EXTENDED-RELEASE TABLETS	IMPURITIES/*Organic Impurities*	*Revision Bulletin (Official April 01, 2018)*	Online	30-Nov-2018	1-Dec-2018	*USP43–NF38*	*USP42–NF37*	This erratum applies to the Revision Bulletin posted on www.uspnf.com only. In the variable definition list in *Analysis*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Change C_U = nominal concentration of the *Sample solution* (mg/mL) to: C_U = nominal concentration of the *Sample solution* (mg/mL) [Note—Disregard any peak less than 0.1%.]
CUPRIC CHLORIDE	ASSAY/ *Procedure*	*USP41–NF36*	1109	30-Nov-2018	1-Dec-2018	*USP43–NF38*	*USP42–NF37*	Line 1 of *Analysis*: Change To the *Sample solution* to: To 50 mL of the *Sample solution*
AZEOTROPIC ISOPROPYL ALCOHOL	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP41–NF36*	2257	30-Nov-2018	1-Dec-2018	*USP43–NF38*	*USP42–NF37*	Line 1 of USP 2-Propanol System Suitability RS: Change It contains 0.1% of each of the following: ethyl

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								ether, acetone, isopropyl alcohol, diisopropyl ether, 1-propanol, and 2-butanol. to: It is a mixture of the following: ethyl ether (0.1%), acetone (0.1%), diisopropyl ether (0.1%), 1-propanol (0.1%), 2-butanol (0.1%), and isopropyl alcohol (99.5%).
AMLODIPINE AND ATORVASTATIN TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*	*First Supplement to USP41–NF36*	8270	30-Nov-2018	1-Dec-2018	*USP43–NF38*	*USP42–NF37*	In the second Calculate statement in *Analysis*: Change ($C_{33}H_{34}FN_2O_5$) to: ($C_{33}H_{35}FN_2O_5$) AND In *Tolerances*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
LIDOCAINE	ASSAY/ *Procedure*	*First Supplement to USP41–NF36*	Online	30-Nov-2018	1-Dec-2018	*USP43–NF38*	*USP42–NF37*	Change ($C_{33}H_{34}FN_2O_5$) to: ($C_{33}H_{35}FN_2O_5$) This erratum applies to the new *USP-NF* ONLINE platform only. Line 2 of *Standard solution*: Change 1 N sodium hydroxide, to: 1 N hydrochloric acid, AND Line 2 of *Sample solution*: Change 1 N sodium hydroxide, to: 1 N hydrochloric acid,

Pagination

- First page « First
- Previous page ‹ Previous
- …
- Page 13
- Page 14
- Page 15
- Page 16
- Page 17
- Page 18
- Page 19
- Page 20
- Page 21
- …
- Next page Next ›
- Last page Last »